Thomas J Mckearn Net Worth

The estimated Net Worth of Thomas J Mckearn is at least $315 Tisíc dollars as of 20 December 2016. Thomas Mckearn owns over 12,316 units of Onconova Therapeutics Inc stock worth over $69,804 and over the last 19 years Thomas sold ONTX stock worth over $245,558.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Thomas Mckearn ONTX stock SEC Form 4 insiders trading

Thomas has made over 4 trades of the Onconova Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Thomas sold 12,316 units of ONTX stock worth $99,513 on 20 December 2016.

The largest trade Thomas's ever made was selling 14,000 units of Onconova Therapeutics Inc stock on 16 March 2016 worth over $115,500. On average, Thomas trades about 1,406 units every 52 days since 2006. As of 20 December 2016 Thomas still owns at least 69,804 units of Onconova Therapeutics Inc stock.

You can see the complete history of Thomas Mckearn stock trades at the bottom of the page.

What's Thomas Mckearn's mailing address?

Thomas's mailing address filed with the SEC is C/O ADVAXIS, INC., TECHNOLOGY CENTER OF NJ, 675 US HWY ONE, NORTH BRUNSWICK, NJ, 08902.

Insiders trading at Onconova Therapeutics Inc

Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683 a Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.

What does Onconova Therapeutics Inc do?

onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.

Complete history of Thomas Mckearn stock trades at Ayala Pharmaceuticals a Onconova Therapeutics Inc

Onconova Therapeutics Inc executives and stock owners

Onconova Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Steven M. Fruchtman,
  CEO, Pres & Director
• Manoj Maniar,
  Senior Vice President - Product Development
• Mark Patrick Guerin CPA,
  Chief Financial Officer
• Terri Shoemaker,
  Director
• James Marino,
  Chairman of the Board
• Anne VanLent,
  Director
• Jack Stover,
  Director
• Viren Mehta,
  Director
• Jerome Groopman,
  Director
• Henry Bienen,
  Director
• Abraham Oler,
  Vice President, Corporate Development and General Counsel
• Mark Guerin,
  Chief Financial Officer
• Steven Fruchtman,
  President, Chief Executive Officer, Director
• Dr. Ramesh Kumar Ph.D.,
  Advisor
• Dr. Mark Stephen Gelder,
  Chief Medical Officer
• Abraham N. Oler J.D., M.B.A., Esq., CFA,
  Sr. VP of Corp. Devel. & Gen. Counsel
• Capital Management, Llc683 ...,
  
• Capital Management, Llc683 ...,
  
• Ramesh Kumar,
  President and CEO
• Michael B Hoffman,
  Director
• E Premkumar Reddy,
  Director
• Capital Partners L P Tyndall,
  10% owner
• Richard Charles Woodman,
  Chief Medical Officer
• Capital Management, Llc 683,
  10% owner
• Healthcare Sa Baxter,
  10% owner
• Ajay Bansal,
  Chief Financial Officer
• Thomas J Mckearn,
  President, R&D
• & Jane Hoffman 2013 Descend...,
  10% owner
• James Altland,
  SVP, Finance & Corp. Develop.
• Healthcare Sabaxter Interna...,
  
• Capital, Llc Armistice Capi...,
  
• Mary Teresa Shoemaker,
  
• Victor M Moyo,
  CHIEF MEDICAL OFFICER
• Mark S. Md Gelder,
  CHIEF MEDICAL OFFICER
• Peter Atadja,
  
• Trafford Clarke,